Icotrokinra's clearance holds through a year, taken as a tablet

Design

Two phase 3, randomised, placebo- and active comparator-controlled trials, reported to week 52

Population

1,505 adults with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 n=774, ADVANCE 2 n=731)

Primary outcome

IGA 0/1 and PASI 90 response, with IGA 0 and PASI 100, through week 52

Effect

About 70-75% IGA 0/1 and PASI 90 during weeks 24-52; about 50% IGA 0 and PASI 100; 85-90% of week-16 responders maintained to week 52

Icotrokinra is an oral peptide that blocks the interleukin-23 receptor — the same axis as the injectable IL-23 antibodies, reached by mouth. ICONIC-ADVANCE 1 and 2 randomised 1,505 adults with moderate-to-severe plaque psoriasis (774 and 731) to icotrokinra 200 mg once daily, placebo crossing to icotrokinra at week 16, or deucravacitinib 6 mg once daily crossing at week 24. This report covers outcomes to week 52.

Clearance rose through week 24 and then held. During weeks 24 to 52, about 70-75% of those randomised to icotrokinra had clear or almost clear skin (IGA 0/1 with at least a 2-grade improvement, and PASI 90), and about 50% were completely clear (IGA 0, PASI 100). Among those already clear or almost clear at week 16, 85-90% still were at week 52. Scalp-specific IGA and patient-reported outcomes were similarly durable. Patients crossing from placebo or from deucravacitinib caught up to the same response rates by week 52.

Safety: adverse events matched placebo through week 16 and were less frequent than deucravacitinib through week 24, with no new signals through a year.

The interest is not the efficacy number, which sits where a good IL-23 agent sits. It is that a patient who would otherwise need injections every eight or twelve weeks may be treatable with a daily tablet. For Indian practice the question is availability and price, neither of which is settled — this is a trial readout, not a product on a shelf.

• Half of patients reaching completely clear skin is the number to quote, not PASI 75
• The 85-90% maintenance figure is the one that matters for a patient asking whether it lasts
• No new safety signal through 52 weeks is reassuring but is not long-term safety data
• Check licensing status before discussing it as an option — this is trial evidence
• Oral dosing matters most for patients who have refused or stopped injectables

Why it matters

It puts IL-23 blockade, until now an injectable class, within reach of a daily tablet.

Don't overread it

The head-to-head advantage over deucravacitinib was established at weeks 16 and 24; the 52-week data are not a controlled comparison.

The statistics, in plain English

These are response rates among patients who stayed in the trial, reported as ranges across two trials rather than single point estimates with confidence intervals — so read them as approximate. The comparison with deucravacitinib was made at weeks 16 and 24, before the crossover, and the 52-week figures are single-arm follow-through, not a controlled comparison at that timepoint.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.